Inconsistent with previously published data regarding the inefficiency of Aβ pathology alone to induce the typical phenotype of AD [36], Banerjee et al. [66] explored the possibility that childhood treatment with cadaveric hGH may eventually lead to AD and reported a group of cadaveric hGH recipients who presented either with early-onset cognitive decline and/or biomarker findings highly indicative of AD. Here, GH1 is linked to Alzheimer disease.